Aligos Therapeutics (ALGS) Free Cash Flow (2021 - 2025)
Aligos Therapeutics filings provide 5 years of Free Cash Flow readings, the most recent being -$21.7 million for Q4 2025.
- On a quarterly basis, Free Cash Flow fell 18.16% to -$21.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$82.5 million, a 2.18% decrease, with the full-year FY2025 number at -$82.5 million, down 2.02% from a year prior.
- Free Cash Flow hit -$21.7 million in Q4 2025 for Aligos Therapeutics, up from -$24.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$13.6 million in Q2 2023 to a low of -$37.8 million in Q4 2021.
- Median Free Cash Flow over the past 5 years was -$21.3 million (2022), compared with a mean of -$22.0 million.
- Biggest five-year swings in Free Cash Flow: soared 55.38% in 2022 and later crashed 43.16% in 2024.
- Aligos Therapeutics' Free Cash Flow stood at -$37.8 million in 2021, then surged by 55.38% to -$16.9 million in 2022, then crashed by 34.28% to -$22.7 million in 2023, then grew by 18.78% to -$18.4 million in 2024, then fell by 18.16% to -$21.7 million in 2025.
- The last three reported values for Free Cash Flow were -$21.7 million (Q4 2025), -$24.3 million (Q3 2025), and -$15.5 million (Q2 2025) per Business Quant data.